XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability
$ in Thousands
2 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance $ 0
Non-cash research and development expense 2,248
Cash receipts from SFJ 750
Change in the fair value of development derivative liability 1,599
Ending balance $ 4,597